It's been a busy month for Retrophin ($RTRX), and CEO Martin Shkreli is capping it off with an IPO filing, looking to take his company from over-the-counter trading to the Nasdaq and pick up $40 million in the process. The biotech recently traded $5 million for Novartis' ($NVS) oxytocin nasal spray with hopes of developing the long-shelved drug into a treatment for schizophrenia and autism, a move that grabbed headlines--though many of them boiled down to "Is Retrophin for real?" The company's pipeline also includes a Phase II treatment for focal segmental glomerulosclerosis and early stage drugs targeting nephrotic syndrome, infantile spasms and neurodegeneration. Filing